Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
03/2003
03/20/2003WO2002047697A8 Fractions of snake blood, their preparation and use as therapeutic agents
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002004520A3 Transporters and ion channels
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055074 For use in therapy of psychic and neurological disorders
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055055 For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children
03/20/2003US20030055032 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
03/20/2003US20030054998 Prolactin induced increase in neural stem cell numbers
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459531A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003CA2458029A1 Methods of treating cytokine mediated diseases
03/19/2003EP1292683A2 Secreted redox proteins
03/19/2003EP1292678A2 G-protein coupled receptors
03/19/2003EP1292671A1 Method for obtaining characterised muscle-derived cell populations and uses
03/19/2003EP1292620A2 Nuclear hormone receptor
03/19/2003EP1292619A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation
03/19/2003EP1292605A2 Antisense modulation of inhibitor of dna binding-1 expression
03/19/2003EP1292324A2 Critical illness neuropathy
03/19/2003EP0702559B1 Multiple botulinum toxins for treating neuromuscular disorders and conditions
03/19/2003CN1404481A Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
03/19/2003CN1404480A Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
03/19/2003CN1404477A 哌嗪和哌啶衍生物 Piperazine and piperidine derivatives
03/19/2003CN1404471A Substituted piperazine compounds
03/19/2003CN1404470A 2-OXo-1-pyrrolidine derivatives, process for preparing them and their uses
03/19/2003CN1404469A 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
03/18/2003US6534483 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
03/18/2003US6534261 Regulation of endogenous gene expression in cells using zinc finger proteins
03/18/2003CA2269994C 7-hetero-bicyclo¬2.2.1|-heptanes
03/18/2003CA2162708C Bicyclic amide derivatives and their use as muscle relaxants
03/13/2003WO2003020759A2 A caspase- 8 binding protein, its preparation and use
03/13/2003WO2003020749A2 Ncam binding compounds
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020278A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
03/13/2003WO2003020257A2 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
03/13/2003WO2003004472A8 Arylamines for the treatment of conditions associated with gsk-3
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067760A3 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002014487A3 Adeno-associated virus-mediated delivery of angiogenic factors
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030049838 Generation of neuronal cell for use in the treatment of nervous system disorders; prepare nutrient broth contain nerve growth factor, inoculate with cells, propagate and monitor cells
03/13/2003US20030049697 Detection of potassium channel modulators for treatment of heart, vascular and endrocrine pathologies; obtain sample, incubate with modulator, monitor effect of modulator on transport protein activity
03/13/2003US20030049271 Diagnosis, therapy of bacteria infections
03/13/2003US20030049266 Induce immunology response usin gpolynucleotide
03/13/2003US20030049245 Methods for sterilizing preparations of digestive enzymes
03/13/2003US20030049208 For delivering a medicant; product includes a coating having a medicament or agent; bioavailabilty; chewing gum product that releases caffiene for improved performance
03/13/2003CA2459937A1 Ncam binding compounds
03/13/2003CA2459136A1 A caspase-8 binding protein, its preparation and use
03/12/2003EP1291360A1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
03/12/2003EP1291346A1 Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
03/12/2003EP1290193A2 Protein phosphatases
03/12/2003EP1290187A2 Humain kinases
03/12/2003EP1290180A2 Drug metabolizing enzymes
03/12/2003EP1290169A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
03/12/2003EP1290167A1 Human kcnq5 potassium channel, methods and compositions thereof
03/12/2003EP1290154A2 The identification and use of effectors and allosteric molecules for the alteration of gene expression
03/12/2003EP1290143A2 Method to determine the differentiation potential of a target cell
03/12/2003EP1289997A1 Macrolides
03/12/2003EP1289993A1 Caspase inhibitors and uses thereof
03/12/2003EP1289983A2 Heteroarylalkanoic acids as integrin receptor antagonists
03/12/2003EP1289965A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
03/12/2003EP1289964A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
03/12/2003EP1289961A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
03/12/2003EP1289960A2 Cycloalkyl alkanoic acids as integrin receptor antagonists
03/12/2003EP1289959A1 Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
03/12/2003EP1289956A1 Chemical compounds
03/12/2003EP1289553A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
03/12/2003EP1289535A2 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
03/12/2003EP1289519A1 Methods of treating androgen deficiency in men using selective antiestrogens
03/12/2003EP1289504A2 Neurotoxin implant
03/12/2003EP1044203B1 3'-epimeric k-252a derivatives
03/12/2003CN1402737A 6-mercapto-cyclodextrin derivs.: resersal agent for drug-induced neuromuscular block
03/12/2003CN1402733A Angiogenic proteins and uses thereof
03/12/2003CN1401317A Use of bismuth subgallate in suppressing formation of nitrogen oxide synthetase
03/11/2003US6531580 Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
03/11/2003US6531492 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
03/11/2003US6531449 Hexahydropyrazolo[4,3,-c]pyridine metabolites
03/06/2003WO2003018836A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease
03/06/2003WO2003018782A2 Differentiation of neural stem cells and therapeutic use theeof
03/06/2003WO2003018758A2 Reagents and methods for smooth muscle therapies
03/06/2003WO2003018756A2 Methods for preparing purified prostaglandin e synthase
03/06/2003WO2003018640A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003WO2003018619A2 Antimicrobial and anti-inflammatory peptides
03/06/2003WO2003018574A1 Rapamycin dialdehydes
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018044A1 New drug
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003017994A1 Amidine derivatives for treating amyloidosis
03/06/2003WO2002102381A9 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
03/06/2003WO2002092122A3 Use of osteopontin for the treatment and/or prevention of neurologic diseases
03/06/2003WO2002086069A3 Secreted proteins
1 ... 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 ... 233